Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28810356 | 1.00 | FDPS (0.39) | FDPSLMNADNM1HRH3L3MBTL1 | |
| SCHEMBL15670951 | 1.00 | FDPS (0.39) | FDPSLMNADNM1HRH3L3MBTL1 | |
| SCHEMBL28809663 | 1.00 | FDPS (0.39) | FDPSLMNADNM1HRH3L3MBTL1 | |
| SCHEMBL14636358 | 1.00 | FDPS (0.39) | FDPSLMNADNM1HRH3L3MBTL1 | |
| SCHEMBL2012868 | 1.00 | FDPS (0.39) | FDPSLMNADNM1HRH3L3MBTL1 | |
| SCHEMBL12469943 | 1.00 | FDPS (0.39) | FDPSLMNADNM1HRH3L3MBTL1 | |
| SCHEMBL23251113 | 1.00 | FDPS (0.39) | FDPSLMNADNM1HRH3L3MBTL1 | |
| SCHEMBL14127423 | 1.00 | FDPS (0.39) | FDPSLMNADNM1HRH3L3MBTL1 | |
| SCHEMBL19441034 | 1.00 | FDPS (0.39) | FDPSLMNADNM1HRH3L3MBTL1 | |
| SCHEMBL12469789 | 1.00 | FDPS (0.39) | FDPSLMNADNM1HRH3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091497-B2 | Pyrano[3,4-b]pyrazine kappa opioid receptor ligands for treating addiction, pruritus, pain, and inflammation | THE ROCKEFELLER UNIVERSITY (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210179629-A1 | PYRANO[3,4-b]PYRAZINE KAPPA OPIOID RECEPTOR LIGANDS FOR TREATING ADDICTION, PRURITUS, PAIN, AND INFLAMMATION | THE ROCKEFELLER UNIVERSITY (US) | 2021-06-17 | — | — | US | disclosed |
| CN-107074890-B | Alkenyl (perfluoroalkyl) phosphinic acids | 默克专利股份公司 | 2019-09-24 | — | — | CN | disclosed |
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-02-15 | — | — | US | disclosed |
| EP-3207047-A1 | ALKENYL (PERFLUOROALKYL) PHOSPHINIC ACID | Merck Patent GmbH (DE) | 2017-08-23 | — | — | EP | disclosed |
| WO-2016058668-A1 | ALKENYL (PERFLUOROALKYL) PHOSPHINIC ACID | MERCK PATENT GMBH (DE) | 2016-04-21 | — | — | WO | disclosed |
| EP-2925768-A1 | COBALTCOMPLEX SALTS | Merck Patent GmbH (DE) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014082704-A1 | COBALTCOMPLEX SALTS | MERCK PATENT GMBH (DE) | 2014-06-05 | — | — | WO | disclosed |
| CN-103687863-A | Compounds containing alkyl-cyano-borate or alkyl-cyano-fluoroborate anions | MERCK PATENT GMBH | 2014-03-26 | — | — | CN | disclosed |
| WO-2011085967-A1 | COMPOUNDS CONTAINING PERFLUOROALKYL-CYANO-ALKOXY-BORATE ANIONS OR PERFLUOROALKYL-CYANO-ALKOXY-FLUORO-BORATE ANIONS | MERCK PATENT GMBH (DE) | 2011-07-21 | — | — | WO | disclosed |
| US-7605271-B2 | Superhigh purity ionic liquid | DAI-ICHI KOGYO SEIYAKU CO., LTD (JP) | 2009-10-20 | — | — | US | disclosed |
| US-20060223995-A1 | Superhigh purity ionic liquid | DAI-ICHI KOGYO SEIYAKU CO., LTD. (JP) | 2006-10-05 | — | — | US | disclosed |
| EP-1707265-A1 | Superhigh purity ionic liquid | DAI-ICHI KOGYO SEIYAKU CO., LTD. (JP) | 2006-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | PDE3A, PDE2A, PDE5A | FDPS 401/4885LMNA 2416/4885DNM1 2192/4885 |
| US-11091497-B2 | Pyrano[3,4-b]pyrazine kappa opioid receptor ligands for treating addiction, pruritus, pain, and inflammation | OPRK1, OPRD1, OPRL1 | FDPS 3395/4885LMNA 4875/4885DNM1 3951/4885 |
| US-20210179629-A1 | PYRANO[3,4-b]PYRAZINE KAPPA OPIOID RECEPTOR LIGANDS FOR TREATING ADDICTION, PRURITUS, PAIN, AND INFLAMMATION | OPRK1, OPRD1, OPRL1 | FDPS 3395/4885LMNA 4875/4885DNM1 3951/4885 |
| US-20060223995-A1 | Superhigh purity ionic liquid | SLC7A5, SLC7A1, SLC43A1 | FDPS 4271/4885LMNA 2206/4885DNM1 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.